Tag: 上海外卖服务自带工作室

Army Scientists Striving to Develop Ebola Vaccine

first_img“Probably the most important thing we can do at this time,” he added, “is to provide some sort of treatment option or vaccine to health care workers who are risking their lives, so they can pass that along in the health care they are providing.” Human testing to evaluate safety of VSV-EBOV is underway at the National Institutes of Health Clinical Center in Bethesda, Maryland. Researchers at the National Institute of Allergy and Infectious Diseases, or NIAID, are conducting an early phase trial to evaluate the VSV-ZEBOV candidate for safety and its ability to generate an immune system response in healthy adults who receive two intramuscular doses. During an interview last week, U.S. Army Medical Research Institute of Infectious Diseases, known as USAMRIID, scientists described their vaccine and drug-development research, development processes and products in development for the Ebola virus, and other infectious diseases. The problem, he added, is that each component in the trivalent vaccine has to go through its own set of clinical trials and FDA approvals for use in people, and that takes time. Dr. John M. Dye Jr., chief in USAMRIID’s Viral Immunology Branch, said dozens of vaccine candidates are being created worldwide, “especially with this outbreak and all of them have to go through an FDA (Food and Drug Administration) regulatory pathway.” USAMRIID is taking the most advanced vaccines forward as quickly as possible, to try to stem the Ebola outbreak, he added. In early stage clinical trials, again designed to assess vaccine safety and immune response, the National Institute of Allergy and Infectious Diseases, part of NIH, will test two versions of the NIAID/GlaxoSmithKline vaccine. One is a bivalent, or two-component, version containing genetic material from Ebola Zaire and Ebola Sudan. The other is a monovalent, or single-component, version that contains only genetic material from Ebola Zaire. Other species, according to the Centers for Disease Control and Prevention, include Sudan virus, Tai Forest virus and Bundibugyo virus. The fifth, Reston virus, has caused disease in monkeys, but not in people. Dr. John M. Dye Jr., chief in USAMRIID’s Viral Immunology Branch, said dozens of vaccine candidates are being created worldwide, “especially with this outbreak and all of them have to go through an FDA (Food and Drug Administration) regulatory pathway.” USAMRIID is taking the most advanced vaccines forward as quickly as possible, to try to stem the Ebola outbreak, he added. “If we do have experimental therapeutics and vaccines that could help,” Dr. Dye said, “it’s going to give some peace of mind to those who are going into [affected] countries” to treat patients. “Pretty much every vaccine that is currently being assessed for FDA approval has been through USAMRIID at one point or another,” Dr. Dye said. Meeting attendees came to consensus on the following points: At the same time, the Walter Reed Army Institute of Research is testing the vaccine candidate as a single dose at its Clinical Trials Center in Silver Spring, Maryland, NIH officials said. During an interview last week, U.S. Army Medical Research Institute of Infectious Diseases, known as USAMRIID, scientists described their vaccine and drug-development research, development processes and products in development for the Ebola virus, and other infectious diseases. Dr. Dye, who has worked at USAMRIID for a decade, said that over the past 10 years, scientists there have made great advances in vaccines and therapeutics. The problem, he added, is that each component in the trivalent vaccine has to go through its own set of clinical trials and FDA approvals for use in people, and that takes time. “This outbreak is [Ebola] Zaire and, honestly, we were lucky it was Zaire,” Dr. Dye said, “because we have the most information and the most therapeutic options and the most vaccine work for Zaire. It’s the one we’ve been working on the longest.” In a statement on its website, the World Health Organization said the two Ebola vaccine candidates in clinical trials also will be tested soon in clinical trials in Africa and Europe. The WHO statement added that officials will work with all stakeholders to accelerate the vaccines’ development and safe use in countries with outbreaks. “The vaccines we’ve been working with here all express one particular protein of the virus, and many of these vaccines have been shown to be 100 percent [effective] in nonhuman primates, or monkey studies,” the viral immunology branch chief said. One vaccine candidate in clinical trials is based on recombinant, or genetically engineered, virus from an animal disease called vesicular stomatitis. An Ebola virus protein is modified into a vesicular stomatitis virus, and that virus acts as a vector, or carrier, to deliver the Ebola protein into the human body. The vaccine is called VSV-EBOV. Most of the vaccine candidates target Ebola Zaire, one of five species of Ebola virus, and the one that’s now causing the West Africa outbreaks. Clinical studies WHO reported that as of Oct. 23, along with more than 10,000 confirmed and suspected cases of Ebola virus disease and nearly 5,000 deaths, at least 450 health care workers have been infected with Ebola virus disease, and 244 have died. It’s important for USAMRIID to keep working on vaccines for all the filoviruses, Dr. Dye said, “because we don’t know what the next outbreak is going to be, but it’s important to realize that just because we have a response against Zaire doesn’t mean we’ve covered everything that we need to.” — Pharmaceutical companies developing the vaccines committed to ramping up production capacity for millions of doses to be available in 2015, with several hundred thousand ready before mid-2015. In a statement on its website, the World Health Organization said the two Ebola vaccine candidates in clinical trials also will be tested soon in clinical trials in Africa and Europe. The WHO statement added that officials will work with all stakeholders to accelerate the vaccines’ development and safe use in countries with outbreaks. Dr. Travis K. Warren, principal investigator in the Division of Molecular and Translational Sciences, said, “the response we’re generating for Ebola virus is also going to contribute to the efforts for Marburg virus, Sudan virus [and] for these broad-spectrum viruses, because we will begin to develop the drug product, the supply of the drug product and the safety information that will be applicable to many different programs.” WASHINGTON – No vaccines or drugs are available yet to protect people worldwide against Ebola Virus Disease, but two potential vaccines are in human safety testing, and scientists at the U.S. Army Medical Research Institute of Infectious Diseases were a critical part of their development. In their medical countermeasures work, USAMRIID scientists already had created a trivalent vaccine — one that contains three components. They are Ebola Zaire, Sudan virus and Marburg virus — another highly lethal virus that’s in the same filovirus group as Ebola. Dr. Travis K. Warren, principal investigator in the Division of Molecular and Translational Sciences, said, “the response we’re generating for Ebola virus is also going to contribute to the efforts for Marburg virus, Sudan virus [and] for these broad-spectrum viruses, because we will begin to develop the drug product, the supply of the drug product and the safety information that will be applicable to many different programs.” In their medical countermeasures work, USAMRIID scientists already had created a trivalent vaccine — one that contains three components. They are Ebola Zaire, Sudan virus and Marburg virus — another highly lethal virus that’s in the same filovirus group as Ebola. Human testing underway In early stage clinical trials, again designed to assess vaccine safety and immune response, the National Institute of Allergy and Infectious Diseases, part of NIH, will test two versions of the NIAID/GlaxoSmithKline vaccine. One is a bivalent, or two-component, version containing genetic material from Ebola Zaire and Ebola Sudan. The other is a monovalent, or single-component, version that contains only genetic material from Ebola Zaire. — Pharmaceutical companies developing the vaccines committed to ramping up production capacity for millions of doses to be available in 2015, with several hundred thousand ready before mid-2015. “The vaccines we’ve been working with here all express one particular protein of the virus, and many of these vaccines have been shown to be 100 percent [effective] in nonhuman primates, or monkey studies,” the viral immunology branch chief said. — Regulatory authorities in countries where the vaccines are manufactured and in Africa committed to supporting this goal by working under extremely short deadlines. USAMRIID, based in Frederick, Maryland, has pioneered research since 1969, to develop medical countermeasures for warfighters against deadly pathogens they might encounter as bioweapons on the battlefield. But lately, its work has gained a more immediate use as a medical tool for ensuring global public health security. USAMRIID has worked with the two Ebola vaccines now in clinical trials at the National Institutes of Health and the Walter Reed Army Institute of Research, and many others over the years, he added. WHO convened an Oct. 24 meeting in Geneva, with high-ranking government representatives from Ebola-affected countries and development partners, civil society, regulatory agencies, vaccine manufacturers and funding agencies to decide how to fast-track testing and deployment of vaccines in enough numbers to affect the Ebola epidemic. Meeting attendees came to consensus on the following points: — Results from phase 1 clinical trials of the most advanced vaccines are expected to be available in December, and efficacy trials in affected countries will begin in the same timeframe. The other vaccine in clinical trials is a recombinant chimpanzee adenovirus, or cold virus. An Ebola virus protein is engineered into a chimpanzee adenovirus to deliver the vaccine, called ChAd-EBOV, into people. At the same time, the Walter Reed Army Institute of Research is testing the vaccine candidate as a single dose at its Clinical Trials Center in Silver Spring, Maryland, NIH officials said. WHO convened an Oct. 24 meeting in Geneva, with high-ranking government representatives from Ebola-affected countries and development partners, civil society, regulatory agencies, vaccine manufacturers and funding agencies to decide how to fast-track testing and deployment of vaccines in enough numbers to affect the Ebola epidemic. WASHINGTON – No vaccines or drugs are available yet to protect people worldwide against Ebola Virus Disease, but two potential vaccines are in human safety testing, and scientists at the U.S. Army Medical Research Institute of Infectious Diseases were a critical part of their development. USAMRIID has worked with the two Ebola vaccines now in clinical trials at the National Institutes of Health and the Walter Reed Army Institute of Research, and many others over the years, he added. USAMRIID, based in Frederick, Maryland, has pioneered research since 1969, to develop medical countermeasures for warfighters against deadly pathogens they might encounter as bioweapons on the battlefield. But lately, its work has gained a more immediate use as a medical tool for ensuring global public health security. The trivalent vaccine is still going forward, Dye said, but a vaccine for Ebola Zaire was spun off in a separate program, “where they’re taking just the Zaire forward and then we’re continuing work on the trivalent cocktail — Zaire, Sudan and Marburg — with the idea that eventually we’re going to have to cover all those bases.” The other vaccine in clinical trials is a recombinant chimpanzee adenovirus, or cold virus. An Ebola virus protein is engineered into a chimpanzee adenovirus to deliver the vaccine, called ChAd-EBOV, into people. “This outbreak is [Ebola] Zaire and, honestly, we were lucky it was Zaire,” Dr. Dye said, “because we have the most information and the most therapeutic options and the most vaccine work for Zaire. It’s the one we’ve been working on the longest.” Human testing underway Other species, according to the Centers for Disease Control and Prevention, include Sudan virus, Tai Forest virus and Bundibugyo virus. The fifth, Reston virus, has caused disease in monkeys, but not in people. By Dialogo November 03, 2014 Dr. Dye, who has worked at USAMRIID for a decade, said that over the past 10 years, scientists there have made great advances in vaccines and therapeutics. One vaccine candidate in clinical trials is based on recombinant, or genetically engineered, virus from an animal disease called vesicular stomatitis. An Ebola virus protein is modified into a vesicular stomatitis virus, and that virus acts as a vector, or carrier, to deliver the Ebola protein into the human body. The vaccine is called VSV-EBOV. It’s important for USAMRIID to keep working on vaccines for all the filoviruses, Dr. Dye said, “because we don’t know what the next outbreak is going to be, but it’s important to realize that just because we have a response against Zaire doesn’t mean we’ve covered everything that we need to.” Most of the vaccine candidates target Ebola Zaire, one of five species of Ebola virus, and the one that’s now causing the West Africa outbreaks. The trivalent vaccine is still going forward, Dye said, but a vaccine for Ebola Zaire was spun off in a separate program, “where they’re taking just the Zaire forward and then we’re continuing work on the trivalent cocktail — Zaire, Sudan and Marburg — with the idea that eventually we’re going to have to cover all those bases.” Human testing to evaluate safety of VSV-EBOV is underway at the National Institutes of Health Clinical Center in Bethesda, Maryland. Researchers at the National Institute of Allergy and Infectious Diseases, or NIAID, are conducting an early phase trial to evaluate the VSV-ZEBOV candidate for safety and its ability to generate an immune system response in healthy adults who receive two intramuscular doses. — Regulatory authorities in countries where the vaccines are manufactured and in Africa committed to supporting this goal by working under extremely short deadlines. — Results from phase 1 clinical trials of the most advanced vaccines are expected to be available in December, and efficacy trials in affected countries will begin in the same timeframe. WHO reported that as of Oct. 23, along with more than 10,000 confirmed and suspected cases of Ebola virus disease and nearly 5,000 deaths, at least 450 health care workers have been infected with Ebola virus disease, and 244 have died. Clinical studies “Pretty much every vaccine that is currently being assessed for FDA approval has been through USAMRIID at one point or another,” Dr. Dye said. “If we do have experimental therapeutics and vaccines that could help,” Dr. Dye said, “it’s going to give some peace of mind to those who are going into [affected] countries” to treat patients. “Probably the most important thing we can do at this time,” he added, “is to provide some sort of treatment option or vaccine to health care workers who are risking their lives, so they can pass that along in the health care they are providing.” I LIKE THIS NEWS ITEMlast_img read more

Read More

Why are people giving their bank accounts the finger?

first_img 21SHARESShareShareSharePrintMailGooglePinterestDiggRedditStumbleuponDeliciousBufferTumblr We’re already using our fingers to unlock our phones, companies use biometric verification for time clocks, and for access to pharmaceuticals by hospital caregivers. So why not for bank account access?Debates have been ongoing about the safety of traditional passwords versus biometric scanning. Data privacy advocates have been quick to warn that your biometric identity would be in someone else’s hands. But according to recent news, it appears that fingerprint account access is now at the point of no return.CNN Money reports that Wells Fargo said that passwords and usernames on mobile phones are an inelegant way to log in to your bank account. The customer-friendly nature of fingerprint readers was a factor that pushed the bank toward biometrics. “Shift, Caps Lock, Enter, numbers — it’s like performing gymnastics on your keypad,” said Secil Watson, Wells Fargo’s head of wholesale internet solutions.The article goes on to say that, “Though the technology has existed for years, data privacy has been a major curveball for banks’ adoption of biometric readers. But the tide is beginning to turn. Fingerprint readers used for Apple Pay and other mobile payment services have made consumers more ready to accept biometric technology for paying bills and banking.” continue reading »last_img read more

Read More

What is simplicity worth?

first_img 5SHARESShareShareSharePrintMailGooglePinterestDiggRedditStumbleuponDeliciousBufferTumblr,Chuck Sutton Chuck Sutton is director, product management, Life & Annuity Solutions, for CUNA Mutual Group, the leading provider of insurance and financial services to credit unions and their members. In this … Web: www.cunamutual.com Details Remember the rise of meal-kit delivery services? Many thought the craze would keep growing, but by the end of 2018, consumers had already begun to lose interest. One reason is many find the seemingly easy solution to dinnertime is too much work. The next wave of food delivery services that’s poised to take off is ready-to-eat meals.1 These arrive on demand, with preparation requiring only heating and serving. Dinnertime solved. Meal kits may have little to do with credit unions, but the trend illustrates something consumers are demonstrating in every aspect of their lives: Simplicity is key. Simplicity PaysToday’s consumers don’t just demand speed, convenience and simplicity – they expect to pay for it, and they’re unsatisfied when they don’t receive it. One 2018 study found that 55% of consumers surveyed were willing to pay more for simpler experiences2. And, 64% said they’re more likely to recommend a brand because it provides simpler experiences and communications2.A more recent study (March 2019) found a gap between what consumers want and what companies deliver. “Brands are under-delivering on simplicity, with about half of consumers saying brands are not meeting their needs.” Additionally, when asked to rank their needs in order of importance, these consumers ranked simplicity among the most important.3Think about this data in terms of your members. Are you delivering the kind of simplified products and services  that drive long-term member satisfaction and loyalty? Simplified Life InsuranceWhen this year’s Insurance Barometer was released by LIMRA in April, one of its top findings confirmed this trend extends to the insurance industry as well. Almost half of Americans, or 47%, said they’re more likely to buy life insurance using simplified underwriting.4 It makes sense that so many insurance companies are moving away from paper applications and toward end-to-end online experiences. And that medical exams and insurance agents are fading into background. Faster and simpler policies, even if they’re more expensive, are taking the industry by storm.5Opportunity at the Intersection of Simplicity and PriceIf you’re still unsure whether your members will really pay more for simplified issue life insurance, consider this: Life insurance costs less than people think.This wild notion is backed up by data, time and time again. And while past studies may have demonstrated that one demographic or another was less-informed about the true cost of life insurance, LIMRA’s 2019 study didn’t limit its survey question to a single age group:“When asked how much a $250,000 20-year level term life insurance policy would be for a healthy 30-year-old, the median estimate was $500 – more than three times the actual cost.”4Life Insurance Awareness Month is a great time to remind your members:That life insurance is valuable and necessaryThat getting life insurance can be faster and easier than they thinkThat simplified life insurance probably costs less than they thinkAnd, it’s a great time to decide to offer your members what they really want, need and are willing to pay for: simplified issue life insurance. last_img read more

Read More

The rise of credit unions in auto finance

first_img ShareShareSharePrintMailGooglePinterestDiggRedditStumbleuponDeliciousBufferTumblr As credit unions consolidate, their membership bases are growing. In 2017, the number of members per credit union grew to nearly 20,000, up from 13,700 in 2012.At the same time, credit unions increased total balances by 10% year-over-year, reaching $972 billion – or 7.7% market share – in 2017. As they grew, credit unions captured more market share in auto – at the expense of banks. Between 2013 and 2018, credit unions’ market share rose 8%, while banks declined at the same rate.To understand how credit unions surpassed banks in auto finance, we analyzed our consumer credit database and found credit unions adopted four strategies. continue reading »last_img read more

Read More

Tamiflu may pose risk of mental side effects

first_imgNov 14, 2006 (CIDRAP News) – Mainly on the basis of reports from Japan, drug manufacturer Roche and US regulators are warning that influenza patients treated with oseltamivir (Tamiflu) may have an increased risk of self-injury and delirium.”People with the flu, particularly children, may be at increased risk of self-injury and confusion shortly after taking Tamiflu and should be closely monitored for signs of unusual behavior,” says a warning that Roche has added to its official product information, according to a company letter posted on the Food and Drug Administration (FDA) Web site.Oseltamivir, a neuraminidase inhibitor, is used both to prevent and to treat flu and is regarded as the best available drug for dealing with a potential pandemic strain of flu. The United States and many other countries are stockpiling it because of the pandemic threat.The warning follows an FDA review of 103 reports of neuropsychiatric adverse events associated with oseltamivir use between Aug 29, 2005, and Jul 6, 2006, of which 95 came from Japan. That compares with 126 such adverse events reported between 1999 and August 2005. About two thirds of the problems were in children and youth (younger than 17 years).A report by the FDA’s Center for Drug Evaluation and Research says the adverse events included three fatal falls—one in a 14-year-old boy who apparently fell to his death from a condominium balcony and two in men. Most of the events (60 of 103) were described as delirium with disturbed behavior. Other problems included “suicidal events,” panic attacks, delusions, convulsions, depressed consciousness, and loss of consciousness.The FDA and Roche both say the contribution of the drug to the adverse events is not known. The FDA report says influenza by itself can lead to neuropsychiatric disorders, but many of the problems reported, especially delirium and suicide attempts, were not typical of those associated with flu alone.Citing factors that seem to implicate oseltamivir in the events, the FDA said most of the problems occurred within a day after the start of treatment, and in many cases the physician suspected the drug was the cause. In addition, many of the patients recovered quickly after they stopped taking oseltamivir.”It is still unclear whether these neuropsychiatric events are drug-related only, disease manifestations alone, or a combination” of the two, the report states.The analysis notes that oseltamivir is used much more widely in Japan, with 24.5 million prescriptions from 2001 thorugh 2005, than in the United States, with 6.5 million prescriptions in the same period. In Japan the product information already includes a warning about possible psychoneurological problems.The FDA report expresses concern that if oseltamivir use in the United States increases to the levels seen in Japan, the number of adverse events will increase as well. “Therefore, it would be prudent to update the U.S. labeling to be similar in scope with the current Japanese labeling,” it says.The Japanese origin of most of the adverse event reports might suggest that the problems are related to genetic characteristics common in Japan, the FDA analysis says. But given the much greater use of the drug in Japan and the possibility of different surveillance practices there, the lack of cases reported in the United States doesn’t constitute good evidence for that hypothesis, it states.The FDA analysis was prepared for the agency’s Pediatric Advisory Committee, which is scheduled to meet Nov 16.The latest developments come about a year after that committee concluded that 12 deaths in Japanese children who had been taking oseltamivir were not related to the drug. The FDA said then that the deaths seemed to be part of a wave of flu-related encephalitis and encephalopathy cases in Japanese children that began in the mid-1990s, before the drug was approved. But the committee asked the FDA to continue monitoring the situation and report again in a year.See also:FDA advice about potential neuropsychiatric side effects of Tamifluhttp://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150758.htmRoche letter about possible riskshttp://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM153422.pdfFDA staff analysis of adverse-event reports concerning TamifluNov 18, 2005, CIDRAP News story “FDA panel: Children’s deaths unrelated to Tamiflu”last_img read more

Read More

Investors wild about the West End

first_imgWould you like to read more?Register for free to finish this article.Sign up now for the following benefits:Four FREE articles of your choice per monthBreaking news, comment and analysis from industry experts as it happensChoose from our portfolio of email newsletters To access this article REGISTER NOWWould you like print copies, app and digital replica access too? SUBSCRIBE for as little as £5 per week.last_img

Read More

At least 16 dead after plane overshoots runway, falls into valley in Kerala

first_imgAccording to the Directorate General of Civil Aviation (DGCA), the Air India Express flight landed on Runway 10 amid visibility of 2,000 metres in heavy rain, but continued running till the end of runway, fell down the valley and broke into two pieces.According to flight-tracking website FlightRadar24, the aircraft circled the airport several times and made two attempts to land.Meanwhile, the DGCA has ordered a detailed inquiry into the incident.The aviation regular, in a latest update, told news agency ANI that the aircraft was at full speed while landing at the Karipur Airport and overshot the runway.Meanwhile, an urgent meeting called by the Civil Aviation Ministry is underway at Rajiv Gandhi Bhawan. DGCA Director-General, officials of the ministry, Airport Authority of India and Air India Express are reportedly present at the meeting.Following the tragedy, Kerala Chief Minister Pinarayi Vijayan informed that he has directed all the concerned officials to make necessary arrangements for rescue and medical supportVijayan has also directed Local Self Government Minister AC Moideen to rush to the accident site.The Kerala CMO, meanwhile, informed that Prime Minister Narendra Modi spoke to CM Pinarayi Vijayan over phone about the plane crash. The CM informed the PM that a team of officials including Kozhikode and Malappuram District Collectors have arrived at the airport and are participating in the rescue operation.PM Modi, in a tweet, also expressed his grief over the loss of lives in the incident and prayed for the recovery of those injured.Pained by the plane accident in Kozhikode. My thoughts are with those who lost their loved ones. May the injured recover at the earliest. Spoke to Kerala CM @vijayanpinarayi Ji regarding the situation. Authorities are at the spot, providing all assistance to the affected.— Narendra Modi (@narendramodi) August 7, 2020President Ram Nath Kovind tweeted that he was “deeply distressed to hear about tragic plane crash of Air India Express flight at Kozhikode”. The President added that he spoke with Kerala Governor Arif Mohammed Khan and inquired about the situation.Union Home Minister Amit Shah tweeted: “Distressed to learn about the tragic accident of Air India Express aircraft in Kozhikode, Kerala.” He added that he has instructed the National Disaster Response Force (NDRF) to reach the accident site at the earliest and assist with the rescue operations.The Air India Express in a statement said, “We regret that there has been an incident regarding our aircraft VT GHK, operating IX 1344 DXB CCJ. Due to crash landing of the flight, it may affect the network but Vande Bharat Mission continues”.The national carrier also informed that help centers are being set up at Sharjah and Dubai, United Arab Emirates.The Consulate General of India, Dubai released the following helpline numbers – 056 546 3903, 0543090572, 0543090572, 0543090575.Kozhikode Collector also shared the Helpline Number 0495 – 2376901 for the relatives of passengers onboard the flight.The chief minister’s office also shared some helpline numbers.Topics : At least 16 people including two pilots have reportedly died after an Air India Express flight from Dubai skidded off the runway and broke in two while landing at Karipur International Airport in Kerala’s Kozhikode district.Dubai-Kozhikode Air India flight (IX-1344), which was part of the Vande Bharat mission that has been bringing back Indians from abroad amid the Coronavirus pandemic, skidded off the runway and plunged deep down 35 ft. into the valley below while landing at the ‘table-top’ airport.The incident occurred at 7:41 p.m. on Friday. Over 100 people are learnt to be injured while at least 15 are critically injured and have been rushed to Kozhikode Medical College and other nearby hospitals.The aircraft with 190 persons onboard battled heavy rains while landing. Although the aircraft broke in two, it, fortunately did not catch fire at the time of landing, thus averting a major disaster.Prayers for the departed souls of Kerala #planecrash #airindia. May God give strength to their families. pic.twitter.com/BUo8lSycso— J.LAWRENCE (@LawrenceLawru) August 7, 2020Police and fire force personnel were immediately pressed into action to carry out rescue operations. An NDRF team has also been rushed to the spot to join the search and rescue mission.As per the Civil Aviation Ministry, there were 174 passengers, 10 infants, 2 pilots and 4 cabin crew onboard the aircraft.last_img read more

Read More

Unai Emery confirms Mesut Ozil and Gabriel Martinelli set to feature against Wolves

first_img Metro Sport ReporterFriday 1 Nov 2019 2:34 pmShare this article via facebookShare this article via twitterShare this article via messengerShare this with Share this article via emailShare this article via flipboardCopy link156Shares Gabriel Martinelli has made a sensational start to his Arsenal career (Picture: Getty)Unai Emery has confirmed both Mesut Ozil and Gabriel Martinelli are in line to feature against Wolves on Saturday.Ozil made an eye-catching return to action during the epic midweek defeat against Liverpool in the Carabao Cup, while Martinelli enhanced his burgeoning reputation with two more goals to take his tally to seven in all competitions this season.‘It is very important to use lots of players because we are playing lots of matches, and it’s a challenge for them to show how they can help us,’ said Emery.‘The performance was positive at Liverpool and I am thinking how they can help us tomorrow.’AdvertisementAdvertisementADVERTISEMENTArsenal are already four points adrift in the race for a top four place and Emery acknowledges Wolves, who took five points of the Gunners last season, represent formidable opposition.More: FootballRio Ferdinand urges Ole Gunnar Solskjaer to drop Manchester United starChelsea defender Fikayo Tomori reveals why he made U-turn over transfer deadline day moveMikel Arteta rates Thomas Partey’s chances of making his Arsenal debut vs Man City‘They won at Man City’s stadium and it is an amazing result, it is very difficult to win there,’ said Emery.‘They lost to Everton and drew in the last minute against Crystal Palace. It depends on each match. Who would have thought they would win at Manchester City? Normally they won’t. We have to respect that result at Man City, how they played at Palace and also how they played at Newcastle. Comment Advertisement Wolves hammered Arsenal 3-1 at Molineux last season (Picture: Getty)‘Now we want to play and prepare our match with respect for them in 50 per cent and imposing our idea in 70 per cent.‘This is my idea in each match and tomorrow is the same. We are thinking and respecting them but above all we need to create our strongest way with the ball, with possession, with our game plan and we defensively we know we need to stop them.’Will Mesut Ozil start against Wolves?Yes0%No0%Share your resultsShare your resultsTweet your resultsMORE: Granit Xhaka was frustrated with Unai Emery over how long he took to award Arsenal captaincyMORE: Jurgen Klopp hails Arsenal youngster Gabriel Martinelli as a ‘talent of the century’ Unai Emery confirms Mesut Ozil and Gabriel Martinelli set to feature against Wolves Advertisementlast_img read more

Read More

Hon Health Minister Recognises Local Lab Techs in Observance of Medical Laboratory Professionals Week

first_img Sharing is caring! Tweet 162 Views   no discussions Share Sharecenter_img The following is a statement by the Hon Minister for Health, Wellness and New Health Investment, Dr Irving McIntyre on Medical Laboratory Professionals Week:Medical Laboratory Professionals Week is being observed this year in Dominica from April 19-25th, under the theme “Laboratory Professionals Get Results”.Medical Laboratory Professionals Week (MLPW) provides the profession with a unique opportunity to increase public understanding of, and appreciation for, clinical laboratory professionals.It is a special time of year when laboratory professionals reflect on the vital role that they play to ensure that patients receive the right tests, the right diagnosis and the right treatment.This year laboratory professionals in the Ministry of Health, Wellness and New Health Investment have had very little time to plan lab week activities, as a result of the significant role that they are playing in the forefront of the fight against the novel corona virus, COVID-19.This is an unprecedented time in the history of not only our nation but of the entire world, as we respond and attempt to mitigate and control the spread of this COVID-19 pandemic.Laboratory professionals are on the front lines 24/7, ensuring that all of the laboratory services continue, machines are functional, resources required are available, tests are conducted maintaining prescribed quality standards, and most importantly, that patients are receiving the appropriate diagnosis and treatment in an efficient manner.Never before has there been greater public focus on this profession since laboratory professionals often work behind the scenes.  Few are aware of the critical testing that laboratory professionals perform every day to save lives, reduce morbidity and help control the cost of care.The emergence of new and complex diseases demands that laboratory professionals remain current in their field of work to help determine and diagnose these diseases.  This, in tandem with advances in analytical science and automation, makes the work of the laboratory professionals more important now than ever.This global COVID-19 pandemic crisis has brought to the fore the need for well-equipped laboratories with highly trained staff and an unrelenting focus on quality.The ability to turn around quality results in quick time is the key to providing information for rapid and efficient patient management. Without this precise and valuable information, medicine would simply become guesswork.The Ministry of Health, Wellness and New Health Investment, and by extension the Government of Dominica, has recognized the importance of having a suitable and well equipped laboratory facility and has therefore invested in infrastructure and equipment, an example being the PCR machine that the Ministry has had since 2018. The new laboratory facilities at the Dominica China Friendship, added to the dedicated staff at the Medical Laboratory, has proven to be very beneficial to the country in the fight against COVID-19.I would like to take this opportunity to thank all the laboratory professionals in Dominica, both in public and private settings, for the critical work that they do in the interest of patient care and public health. Beyond meeting the public need, the celebration of Medical Laboratory Professionals Week will help increase recognition for the profession as it improves the individual’s sense of self-worth.Further, as the various professional groups within laboratory practice work together, the sense of unity and purpose necessary to further the goals of all laboratory professionals is reinforced.Whatever the setting — behind the scenes or out in our communities — laboratory professionals are by our side, working as key members of the health care team.From April 19-25, please join the Ministry of Health and our laboratory professionals in celebrating Medical Laboratory Professionals Week and let us recognize their vital role in promoting and protecting our health.Hon Health Minister, Dr Irving McIntyre Share LifestyleLocalNews Hon Health Minister Recognises Local Lab Techs in Observance of Medical Laboratory Professionals Week by: – April 22, 2020last_img read more

Read More

Pattaya Sport Club Golf Schedule – Friday July 5, 2019 –…

first_imgDATE: Fri05Set 06Sun07Mon08Tue09Wed10Thu11Fri12 Green ValleySiam Old CouresSiam Old Coures Bunker BoysPattavia Retox Game OnPlutaluang I Rovers Pleasant ValleyEastern Star Cafe Kronborg Siam Country TBA Billabong GolfBurapha Pattana The LinksEastern Star PSC Green Valley The next PSC monthly golf tournament is a 2-Person BBStableford event at Laem Chabang C.C. on July 15 Valley View HackersGreen Valley Green ValleyGreen ValleyGreen Valley Pleasant Valley Pattavia Lewiinski’sSiam Old Coures PattanaGreen ValleyKhao Kheow The Bunker Boys meet at Woody’s Bar on Soi Skaw Beach for golf outings every Monday, Wednesday and Friday (www.bunkersociety.com) or call 094368 3580, 081 788 2338 or 087 693 7803. Transportation leaves from Cafe Kronborg on Soi Diana Inn at 8:15 a.m. on Mondays and Thursdays, (contact Dave on tel. 038 602 2117). Colin’s Bar plays golf Sun/Mon/Wed & Fri (www.colinsbar.com). The Growling Swan plays golf on Monday & Thursday (www.thegrowlingswan.com). Lewinski’s in Soi Pattayaland 1 (Soi 13/3), play Mondays, Wednesdays and Fridays. Transport is available, call Marcus on 089 503 9179 for further information and booking. The Pattaya Links Hotel Golf Society departs from Soi Buakhao on Monday, Wednesday and Friday. Call Phil on 0625 933 380 or visit www.thelinkshotelpattaya.com. The Golf Club is located on Soij LK Metro. Call Phil on 090 769 3778.  Tropical Golf meets at BJ’s Holiday Lodge at 8am on Tuesday’ & Friday. Call Derek on 089 034 0629. Retox Golf – Tel. (Paul) 0923744276, Email [email protected]center_img Tropical GolfPleasant Valley Growling Swan The Players Lounge GreenwoodPleasant ValleyKhao Kheow The Golf ClubEastern Star Sugar ShackPlutaluang Le KataiPleasant Valley Khao KheowGreenwoodPattaya C.C. PhoenixGreen ValleyBurapha Treasure Hill Laem ChabangGreenwoodKhao Kheow Eastern StarGreenwood Harry’s Golf Laem ChabangThe EmeraldKhao KheowPlutaluang Burapha Apple’s IrishKhao Kheow Colin’s GolfCrystal BayGreen Valley TBA Outback Golf Bar PhoenixBuraphalast_img read more

Read More